Etanercept improves the health-related quality of life of patients with psoriasis: results of a phase III randomized clinical trial.
rct · Level II
Where this comes from
- Record sourced from PubMed, PMID 16243150.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
In this randomized, double-blind, phase III trial, patients with psoriasis received etanercept for 24 weeks or placebo for 12 weeks followed by etanercept for 12 weeks. At week 12, improvement in Dermatology Life Quality Index was 47% to 61% with etanercept compared with 11% with placebo (P < .0001). Etanercept rapidly and substantially improved patients' health-related quality of life.
Medical subject headings
- Immunoglobulin G
- Psoriasis
- Quality of Life
- Receptors, Tumor Necrosis Factor